Dr. Igor Tetko (coordinator) obtained MSc degree (with honor) from Moscow Institute of Physics and Technology (MIPT) and PhD in bioorganic chemistry from the Ukrainian Academy of Sciences (1994). He did his postdoctoral study in the University of Lausanne in neuroinformatics. Since 2001 Dr. Tetko is employed at Helmholtz Zentrum München, where he is Chemoinformatics group leader at the Institute of Structural Biology. He is also CEO of BigChem GmbH, which provides informatics solution for big data analysis in life sciences. In 2011 he completed H.D.R (habilitation) in chemoinformatics from the University of Strasbourg. Dr Tetko co-authored more than 150 publications in chemoinformatics, bioinformatics, neuroinformatics, computational chemistry, environmental toxicity and machine learning. He was group leader in several international projects (FP7 CADASTER, NATO, INTAS-INFO, etc.) as well as coordinated Virtual Computational Chemistry Laboratory (VCCLAB) and FP7 Marie Curie ITN “Environmental ChemOinformatics”. Dr. Tetko received national GO-Bio BMBF awards (2006 and 2011) and was founder and CSO of eADMET GmbH company. His current research interests include development of computational tools for computer-aided drug discovery and life sciences.
Dr. Kamyar Hadian is currently the Head of the ‘Assay Development and Screening Platform’ at the HelmholtzZentrum München in Munich/Germany and in parallel he is Adjunct Associate Research Scientist at the Columbia University in New York/USA. He has in-depth experience in designing and running biochemical as well as cell-based assays for High-Throughput and High-Content Screening in various disease areas such as Cancer, Diabetes, Virology, Immunology and more. His current research focus the identification and validation of novel molecular targets within Ubiquitin Signaling pathways and the subsequent development of strategies to interfere with these targets. Before that, Kamyar studied Biology at the Technical University of Munich (TUM) and gained his PhD at the HelmholtzZentrum München/Ludwig Maximilians University (LMU) in the field of Virology (HIV research). After a short PostDoc period in the field of NF-kB signaling, he was appointed the Head of ‘Assay Development and Screening Platform’ at the HelmholtzZentrum München in 2010.